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To determine the scaling factors required for inclusion of renal drug glucuronidation clearance in the prediction of total clearance
via glucuronidation (CLUGT).
METHODS
Microsomal protein per gram of kidney (MPPGK) was determined for human ‘mixed’ kidney (n = 5) microsomes (MKM). The
glucuronidation activities of deferiprone (DEF), propofol (PRO) and zidovudine (AZT) byMKMand paired cortical (KCM) andmedullary
(KMM)microsomesweremeasured, alongwith the UGT 1A6, 1A9 and 2B7 protein contents of each enzyme source. Unbound intrinsic
clearances (CLint,u,UGT) for PRO and morphine (MOR; 3- and 6-) glucuronidation by MKM, human liver microsomes (HLM) and re-
combinant UGT1A9 and 2B7were additionally determined. Data were scaled using in vitro–in vivo extrapolation (IV–IVE) approaches to
assess the influence of renal CLint,u,UGT on the prediction accuracy of the calculated CLUGT values of PRO and MOR.
RESULTS
MPPGK was 9.3 ± 2.0 mg g1 (mean ± SD). The respective rates of DEF (UGT1A6), PRO (UGT1A9) and AZT (UGT2B7)
glucuronidation by KCMwere 1.4-, 5.2- and 10.5-fold higher than those for KMM. UGT 1A6, 1A9 and 2B7 were the only enzymes
expressed in kidney. Consistent with the activity data, the abundance of each of these enzymes was greater in KCM than in KMM.
The abundance of UGT1A9 in MKM (61.3 pmol mg1) was 2.7 fold higher than that reported for HLM.
CONCLUSIONS
Scaled renal PRO glucuronidation CLint,u,UGT was double that of liver. Renal CLint,u,UGT should be accounted for in the IV–IVE of
UGT1A9 and considered for UGT1A6 and 2B7 substrates.WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Multiple drugs, non-drug xenobiotics and endobiotics are glucuronidated by human kidney.
• UDP-glucuronosyltransferase (UGT) 1A proteins and UGT2B7 are variably expressed in the tubule components of the human
nephron.© 2016 The British Pharmacological Society DOI:10.1111/bcp.12889
K. M. Knights et al.• Development of kidney specific in vitro–in vivo extrapolation (IV–IVE) approaches is hampered by the limited availability of mi-
crosomal protein per gram of kidney (MPPGK) and knowledge of the content and anatomic distribution of individual UGT
enzymes.
WHAT THIS STUDY ADDS
• This study provides scaling factors to assess the relative contribution of the kidney to renal drug clearance via glucuronidation.
• It demonstrates anatomic differences in renal glucuronidation activity and provides data on the contents of UGT1A6, UGT1A9
and UGT2B7 in human kidney cortex and medulla.
• It establishes that UGT1A9 is 2.7-fold more abundant in human kidney microsomes than hepatic microsomes, indicating the
need to include renal glucuronidation unbound intrinsic clearance in IV–IVE predictions for substrates glucuronidated by
UGT1A9.Introduction
The human kidney has an array of functions that include the
regulation of blood osmolarity, volume, ionic composition
and pH, the production of renin, 1,25-dihydroxyvitamin D,
erythropoietin, prostaglandins and bradykinin, and the
excretion of endogenous metabolites and xenobiotics. The
cortex is characterized by the presence of glomeruli, tufts of
capillaries and numerous convoluted epithelial structures
that form the renal tubules. In contrast, the medulla consists
only of tubules and renal blood vessels. A previous study from
this laboratory identified that UDP-glucuronosyltransferase
(UGT) 1A proteins and UGT2B7 are variably expressed
throughout the tubule components of the human nephron
[1]. The greatest expression of UGT1A proteins occurred in
the cortical proximal convoluted tubules, while variable and
lower expression of UGT2B7 was observed in both cortical
and medullary tubules. Consistent with a high to low gradi-
ent of UGT1A and UGT2B7 expression from the outer cortex
through to the inner medulla, we further demonstrated that
the intrinsic clearance for S-naproxen glucuronidation,
which is catalyzed predominantly by UGT2B7 (with lesser
contributions from UGT 1A6 and 1A9 [2]), was 4.5-fold
higher in kidney cortical microsomes (KCM) compared with
kidney medullary microsomes (KMM) [1]. Other reports have
similarly demonstrated lower glucuronidation activity in re-
nal medulla [3–5].
Multiple drugs, non-drug xenobiotics and endobiotics,
including paracetamol, carbamazepine, codeine, dapa-
gliflozin [6], fatty acids, furosemide, gemfibrozil, ibuprofen,
ketoprofen, leukotrienes, mefenamic acid, mycophenolic
acid, naloxone, naproxen, prostaglandins, propofol (PRO),
retigabine and valproic acid have been shown to be
glucuronidated by whole human kidney microsomes [[7, 8]
and references therein]. Indeed, specific activities for the
glucuronidation of several drugs (e.g. dapagliflozin,
mycophenolic acid and PRO) by kidney exceeds that of liver
[6, 9–11], and there are in vivo data suggesting that renal
metabolism contributes significantly to PRO clearance [12].
Despite these observations, reliable kidney-specific in vitro–
in vivo extrapolation (IV–IVE) models are not yet available
and inclusion of renal glucuronidation data in IV–IVE studies
has been limited [9, 13–15]. In particular, the development
of kidney-specific IV–IVE models has been hampered by lim-
ited data of microsomal protein per gram of kidney (MPPGK)
[13, 14] and knowledge of the abundance and anatomic
distribution of individual renal UGT enzymes. Both are1154 Br J Clin Pharmacol (2016) 81 1153–1164essential for generating the scaling factors required to convert
in vitro enzyme kinetic data to an in vivo drug clearance via
glucuronidation [16].
Quantitative RT-PCR is used to determine UGT mRNA
expression [17, 18] while quantification of UGT protein con-
tent has recently utilized isotopically labelled peptides and
nano-UPLC-MS/MS analyses [19–22]. The latter studies have
principally used human liver microsomes (HLM). By contrast,
data from human kidney are limited to reports of one to two
individuals, the use of pooled kidney microsomes or kidney
homogenate [19, 23, 24].
In this study we report MPPGK using five human kidneys
and the results of comparative studies of UGT enzyme activity
coupled with UGT protein quantification using mixed
(whole) kidney microsomes (MKM), KCM, KMM and
recombinant human UGT1A9 and UGT2B7. For the first time
we provide data on the anatomic distribution and content of
UGT 1A6, 1A9 and 2B7, identify the applicability of MKM for
in vitro studies and show significant correlations between
renal UGT enzyme content and activity. Additionally,
unbound intrinsic glucuronidation clearances (CLint,u,UGT)
were determined for PRO and morphine (MOR) 3- and 6-
glucuronidation using MKM, human liver microsomes
(HLM) and UGT1A9 and UGT2B7. These data were then
scaled to assess the impact of renal CLint,u,UGT on the predic-
tion of IV–IVE for total CL via glucuronidation for PRO and
MOR.Methods
Materials
Alamethicin (from Trichoderma viride) was purchased from A.
G. Scientific (San Diego, CA, USA). Zidovudine (AZT), AZT-
glucuronide, β-estradiol (β-E2), β-estradiol-3-D-glucuronide,
MOR 3-glucuronide (MOR(3-G)), PRO, testosterone (TST),
TST-17-glucuronide and trifluoperazine (TFP) from Sigma-
Aldrich (Sydney, Australia), deferiprone-3-O-glucuronide
and PRO glucuronide from Toronto Research Chemicals
(Toronto, ON, Canada), MOR from GlaxoSmithKline
(Melbourne, Australia) and MOR 6-glucuronide (MOR(6-G))
from Salford Ultrafine Chemicals (Manchester, UK).
Deferiprone (DEF) was provided by Dr John Connelly
(Apopharma Inc., Toronto, ON, Canada). For UGT protein
quantification, stable isotope labelled (SIL) proteotypic pep-
tides in aqueous solution (1 nmol 200 μl–1) containing 5 or
Scaling factors for renal drug and xenobiotic glucuronidation clearance20% acetonitrile were purchased from Thermo Biopolymers
(Ulm, Germany; Material No. HPA97QP010, >97% purity).
Ammonium bicarbonate, formic acid, acetic acid,
iodoacetamide, dithiothreitol and β-casein were purchased
from Sigma-Aldrich (St Louis, MO, USA), acetonitrile (HPLC
grade) from Fisher Scientific (Pittsburg, PA, USA) and trypsin
Gold mass spectrometry grade from Promega (Madison, WI,
USA). Pooled HLM (150 donor pool; equal number of male
and female donors) and UGT1A9 (batch 2 228 592) and
UGT2B7 (batch 38 943) Supersomes™ were provided by
Corning Gentest (Palo Alto, CA, USA). All other reagents
and solvents used were of the highest analytical grade
available.
Human kidney tissue and kidney microsomes
Kidney tissue from Caucasians undergoing radical nephrec-
tomy formalignant disease was provided by the joint FlindersRecovery factor¼microsomal cytochrome c reductase nmol per tissue sampleð Þ
homogenate cytochrome c reductase nmol per tissue sampleð Þ (1)Medical Centre/Repatriation General Hospital Tissue Bank
(Adelaide, South Australia). Approval for the collection andMPPGK mg g1
  ¼ specific activity homogenate nmol cyt c reducedmin
1mg1
  mg homogenate protein g1 kidney 
specific activity microsomes nmol cyt c reducedmin1mg1
 
(2)use of human kidney tissue for in vitro studies was obtained
from the Southern Adelaide Clinical Human Research
Ethics Committee. All tissue used was distant from the pri-
mary tumour and was reported by a specialist histopatholo-
gist to be histologically normal for the age of the donors
(43–79 years), with only benign nephrosclerosis and
hypertensive-like vascular changes observed. Whole kidney
(mixed cortical/medullary) tissue was available from two fe-
males (K12-K13) and three males (K14-K16). Paired cortical
and medullary tissue (both obtained from the same kidney)
was available from five males (K2, K7, K9-K11, for details of
individual subjects refer to Supporting Information Table S1).
Mixed kidney microsomes (MKM, n = 5), kidney cortical
microsomes (KCM, n = 5) and kidney medullary microsomes
(KMM, n = 5) were prepared by differential ultracentrifuga-
tion as detailed by Tsoutsikos et al. [25]. Microsomal protein
was resuspended either in Na2HPO4, pH 7.4 containing 20%
(w/v) glycerol (for UGT activity assays) or buffer only for
UGT protein quantification. MKM, KCM and KMM pools
were prepared by combining equal protein amounts of micro-
somes from the relevant kidneys. Total protein concentration
was measured [26] and all samples stored at80°C until used.Determination of microsomal protein g–1 of
kidney (MPPGK)
Correction factors for the loss of kidney microsomal protein
during preparation of MKM (K12-K16) were determined
by measurement of NADPH cytochrome c reductase
activity. Briefly, either homogenate or microsomal protein
(0.1 mg ml1) was added to a solution (2.2 ml) containing
cytochrome c (5 μM), potassium cyanide (300 μM) and 0.1 M
phosphate buffer (pH 6.8) and preincubated (5 min, 37°C).
Samples (1 ml) were transferred to two quartz cuvettes. Water
(10 μl) was added to the reference cuvette and NADPH
(10 mM, 10 μl) added to the sample cuvette. Absorbance was
monitored at 550 nm and NADPH cytochrome c reductase ac-
tivity calculated using an extinction coefficient of
27.7 cm–1 mM–1 [27, 28]. The recovery of microsomal protein,
and hence fraction of microsomal protein loss during prepa-
ration, was determined as (equation (1)):Values of MPPGK corrected for microsomal protein loss
during preparation were determined using equation (2) [29]:Human kidney microsomal UGT activities
Kidney microsomal UGT 1A1, 1A4, 1A6, 1A9, 2B7 and
2B15/17 activities were determined using β-E2, TFP, DEF,
PRO, AZT and TST as the respective enzyme selective sub-
strates [30]. For all activity studies the probe substrate con-
centrations were four to five times the approximate Km or
S50 for each compound: β-E2 50 μM (S50 10 μM, [31]), DEF
20 mM (Km 4 mM, [32]), PRO 500 μM (Km 125 μM, [33]), AZT
5 mM (Km 1 mM, [34]) and TST 30 μM (Km 6 μM, [35]). How-
ever, due to the substrate inhibition observed with TFP
glucuronidation, experiments were performed at the sub-
strate Km (60 μM, [36]). Activity assays were performed in trip-
licate with MKM (n = 5), KCM (n = 5) and KMM (n = 4).
Insufficient KMM was available for K11 for activity studies.
HLM were used as the positive control in all activity studies.
Microsomal protein concentrations, incubation compo-
nents, duration of incubation, reaction termination proce-
dure and quantification of β-E2, DEF, PRO, AZT, TST and TFP
glucuronides by HPLC were as described in previous publica-
tions from this laboratory [31–36]. Overall within-day repro-
ducibilities were determined for each assay by measuring
glucuronide formation in 8–10 separate incubations of theBr J Clin Pharmacol (2016) 81 1153–1164 1155
K. M. Knights et al.same batch of pooled HLM at three substrate concentrations
(low, mid, high) that spanned the ranges used to characterize
enzyme kinetic parameters. Coefficients of variation ranged
from 1.8% to 6.9%. The lower limits of quantification
assessed as three times background noise, ranged from 0.002
to 0.005 μM, which corresponds to rates of glucuronide for-
mation of <0.5 pmol min1 mg1.PRO glucuronidation and MOR 3- and
6-glucuronidation kinetics by HLM, MKM and
recombinant UGT1A9 and UGT2B7
The kinetics of PRO (10 – 300 μM) glucuronidation and
MOR (100 – 3000 μM) 3- and 6-glucuronidation by pooled
HLM and pooled MKM in the presence of 2% (w/v) BSA
and recombinant UGT1A9 and UGT2B7 (Supersomes) were
determined according to Rowland et al. [33] and
Uchaipichat et al. [37], respectively. The protein concentra-
tion of MKM and HLM present in incubations was
0.5 mg ml1, while the protein concentration of UGT1A9
and UGT2B7 Supersomes in incubations was 0.25 mg ml1
and 1 mg ml1, respectively. PRO, but not MOR [38], binds
to HLM plus BSA. Thus, the previously determined fu,mic
value of 0.20 was used to correct for PRO binding to incuba-
tion constituents [33].Quantification of human kidney microsomal
UGTs and recombinant (Supersome) UGT1A9
and UGT2B7
Protein fromMKM, KCM and KMMwas diluted to 1 mg ml1
with Na2HPO4 and stored at 80°C. Samples (1 μg) of recom-
binant UGT1A9 and UGT2B7 were added to 19 μg of rat liver
microsomes (final protein concentration 20 μg per sample).
Samples were analyzed using minor modifications of previ-
ously published methods [19, 20, 39]. Briefly, microsomal
protein (20 μg, 20 μl of 1 mg ml1 suspension) was added to
a solution of ammonium bicarbonate (50 μl, 50 mM), β-casein
(0.5 μg, 10 μl of 0.05 mg ml1) and dithiothreitol (10 μl,
40 mM). Following denaturation and reduction at 65°C, sam-
ples were carbamidomethylated with iodoacetamide (10 μl,
135 mM). Trypsin (1 μg, 10 μl of 0.1 mg ml1) was then added
to give a microsomal protein to trypsin ratio of 20 : 1 in each
sample. Samples were then digested for 4 h at 37°C. Following
the addition of acetonitrile to terminate the digestionTable 1
Glucuronidation rates of DEF, PRO and AZT and contents of UGT 1A6, 1A9
UGT contents, enzyme activities and normalized enzyme activities represen
the MKM pool (K12-K16) normalized for UGT content are the means of trip
MKM
UGT
enzyme
UGT content
(pmol-UGT mg1)
UGT activity
(pmol-G† min–1 mg–1)
1 A6 4.7 ± 1.4 (3.5, 5.9) 21 019 ± 7836 (14 151, 27 887)
1 A9 61.3 ± 20.1 (44.3, 78.3) 5656 ± 2191 (3736, 7576)
2B7 37.6 ± 17.4 (22.3, 52.9) 1229 ± 598 (705, 1753)
†pmol-G refers to formation of DEF glucuronide (UGT1A6), PRO glucuronide
1156 Br J Clin Pharmacol (2016) 81 1153–1164reaction, a solution (10 μl) containing SIL peptides (1 pmol
of each) was added to each sample. Residual acetonitrile was
removed in a vacuum before treating with solid phase extrac-
tion (Strata-X 33u Polymeric Reversed Phase, 10 mg ml1,
Phenomenex, Torrance, CA, USA). The solid phase extraction
eluate was evaporated to dryness under vacuum and
reconstituted in 50 μl modified mobile phase A (water/ace-
tonitrile/formic acid 98/2/0.1; i.e. 2% ACN instead of 1%)
before analysis by nanobore UPLC-MS/MS (selected/multi-
ple reaction monitoring mode). Mobile phase B was 100%
acetonitrile. The chromatographic and mass spectrometric
instrumentation and conditions were as described previ-
ously [20]. The separation conditions were 100% A at start,
reducing to 58% A at 24 min, then 5% A at 24.5 min for
3 min and 100% A at 28 min for 7 min (total run time
35 min). Multiple reaction monitoring (MRM) data were
processed using MultiQuant 2.0 (AB SCIEX). Peaks were
smoothed prior to integration and area ratios of
unlabelled/SIL peptides were determined using the sum of
the two MRMs monitored.Data analyses
All kidney microsomal UGT activities were performed in trip-
licate and the values averaged to obtain a single value for each
individual kidney. The variation between samples was <5%.
Data are reported as mean ± SD (n = 5 kidneys). Correlations
between UGT protein content in MKM, KCM and KMM and
the respective glucuronidation activities and correlations be-
tween the microsomal contents of UGT1A6/UGT1A9,
UGT1A6/UGT2B7 and UGT1A9/UGT2B7 were assessed using
the non-parametric Spearman rank method. A value of
P < 0.05 was considered statistically significant. PRO and
MOR glucuronidation kinetic data were fitted with the
Michaelis–Menten equation using EnzFitter (version 2.0;
Biosoft, Cambridge, UK).
Unbound intrinsic clearance (CLint,u) values for PRO and
MOR glucuronidation by MKM and HLM were calculated as
Vmax/Km and subsequently scaled for microsomal protein
yield (mg g1) and organ weight (g kg1 body weight) to pro-
vide a whole organ CLint,u,UGT (ml min
1 kg1). The respec-
tive microsomal protein yields (mg g1 tissue) and organ
weights (g kg1 body weight) used in calculations were
9.3 mg g1 (see Results section) and 4.5 g kg1 for kidney
[15], and 32 mg g1 [16] and 21.4 g kg1 [15] for liver. In theand 2B7 using mixed kidney microsomes (MKM). Tabulated data for
t the mean ± SD (95% CI), n = 5 (K12-K16). UGT enzyme activities of
licate determinations
MKM pool
Normalized UGT activity
(pmol-G† min–1 pmol-UGT)
Normalized UGT activity
(pmol-G† min–1 pmol-UGT)
4395 ± 639 (3835, 4955) 4008
92 ± 6 (87, 97) 103
33 ± 2 (31, 35) 31
(UGT1A9), or AZT glucuronide (UGT2B7).
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Scaling factors for renal drug and xenobiotic glucuronidation clearanceabsence of a kidney-specific model, the whole organ CLint,u,
UGT values were scaled using the well-stirred model to give a
predicted total CL via glucuronidation (CLUGT) for both
kidney and liver (equation (3)).
CLUGT ¼
Q x f u;b x CLint;u;UGT
Q þ f u;b x CLint;u;UGT
  (3)
Organ blood flows (Q) were taken as 16.4 ml min1 kg1
for kidney and 20.7 ml min1 kg1 for liver [15]).The fraction
of PRO unbound in blood was taken as 0.015 [15], assuming a
blood : plasma concentration ratio of 1.0. The fraction of a
PRO dose eliminated via glucuronidation was taken as 53%
[14], systemic clearance as 108 l h1 and clearance via
glucuronidation as 57 l h1 [33].
Mean in vivo disposition data for MOR were calculated
from values of individual studies reported in the review of
Milne et al. [40]: plasma clearance following intravenous ad-
ministration 86.1 l h1, percent urinary recoveries of MOR
3- and 6-glucuronides, 55% and 10.2%, respectively, fraction
or MOR unbound in plasma, 0.75 and blood/plasma concen-
tration ratio 1.15.ts
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Determination of MPPGK
The average weight of mixed (cortical/medullary) kidney
tissue available for preparation of MKM was 0.9 ± 0.2 g.
Activities of cytochrome c reductase in the mixed kidney
homogenate fractions and matched microsomal fractions
were 3.3 ± 0.9 (95% CI 2.5, 4.1) μmol min1 g1 and
19.1 ± 4.8 (95% CI 14.9, 23.3) μmol min1 g1, respectively.
The average percentage of microsomal protein lost during
preparation was 33.9 ± 11.8% (95% CI 23.5, 44.3), while the
mean MPPGK corrected for loss of microsomal protein was
9.3 ± 2.0 mg g1 (95% CI 7.6, 11).Ta
b
le
2
G
lu
cu
ro
n
id
at
io
n
ra
te
s
of
D
EF
,P
RO
an
d
A
Z
T
an
d
co
nt
en
ti
vi
ti
es
an
d
no
rm
al
iz
ed
en
zy
m
e
ac
ti
vi
ti
es
re
pr
es
en
t
th
e
of
tr
ip
lic
at
e
de
te
rm
in
at
io
n
s
U
G
T
en
zy
m
e
U
G
T
co
n
te
n
t
(p
m
o
l-
U
G
T
m
g
1
)
C
o
n
te
n
t
ra
ti
o
U
G
T
ac
t
(p
m
o
l-
G
K
C
M
K
M
M
C
:
M
K
C
M
U
G
T
1
A
6
3.
5
±
2.
1
(1
.7
,5
.3
)
1.
6
±
0.
7
(1
,2
.2
)
2.
7
±
2.
2
(0
.8
,4
.6
)
10
50
3
±
(4
02
7
,1
U
G
T
1
A
9
40
±
19
.1
(2
4,
56
)
7.
5
±
2.
4
(5
,9
)
6.
2
±
4.
5
(3
.2
,9
.2
)
50
7
2
±
2
(2
56
2
,7
U
G
T
2
B
7
24
.8
±
15
.2
(1
2,
38
)
4.
4
±
1.
8
(2
.9
,5
.9
)
7.
2
±
6.
2
(1
.8
,1
2.
6
)
57
7
±
41
(2
12
,9
4
†
p
m
o
l-G
re
fe
rs
to
fo
rm
at
io
n
of
D
EF
g
lu
cu
ro
ni
de
(U
G
T1Mixed kidney microsomal UGT activities
Incubations of pooled MKM did not form the glucuronides of
β-E2 (UGT1A1), TFP (UGT1A4) or TST (UGT 2B15/2B17). In
contrast, HLM (used as a positive control) catalyzed the
glucuronidation of β-E2, TFP and TST with respective mean
rates of 348, 350 and 108 pmol min1 mg1. The mean
rates of DEF (UGT1A6), PRO (UGT1A9) and AZT (UGT2B7)
glucuronidation by pooled MKM were high, 18 999, 6309
and 1183 pmol min1 mg1, respectively. Subsequent
activity studies using individual MKM from K12-K16 and
DEF, PRO and AZT established that the rates of
glucuronidation of each probe substrate when expressed
as either pmol glucuronide (pmol-G) min–1 mg1 micro-
somal protein or as activity normalized for UGT expression
(pmol-G min1 pmol1 UGT), were comparable with the
MKM pool (Table 1).Br J Clin Pharmacol (2016) 81 1153–1164 1157
Figure 1
UGT protein concentration (pmol-UGTmg1 microsomal protein) of
UGT1A6, UGT1A9 and UGT2B7 of human mixed kidney microsomes
(MKM, n = 5), kidney cortical microsomes (KCM, n = 5) and kidney
medullary microsomes (KMM, n = 5). Kidney microsomal samples
were analyzed at least in duplicate and the values were averaged to
obtain a single value for each individual kidney. K2, K7, K9,
K10, K11, K12, K13, K14, K15, K16
Figure 2
Correlations between (A) deferiprone glucuronidation and UGT1A6 content,
(B) propofol glucuronidation and UGT1A9 content and (C) AZT
glucuronidation and UGT2B7 content of MKM , KCM and KMM .
Correlationcoefficients rsweredeterminedusing theSpearman rankmethod.
K. M. Knights et al.Cortical and medullary microsomal UGT
activities
Similar to MKM, formation of β-E2, TFP or TST glucuronides
was not observed using pooled KCM and KMM. Rates of for-
mation (pmol-G min1 mg1 microsomal protein) of DEF
(UGT1A6), PRO (UGT1A9) and AZT (UGT2B7) glucuronides
by KCM were 1.4-fold, 5.2-fold and 10.5-fold greater, respec-
tively, than for KMM (Table 2). The average cortical : medullary
(C : M) ratios of enzyme activity normalized for UGT content
were 1.0, 1.1 and 1.8 for UGT 1A6, 1A9 and 2B7, respectively.
Comparable enzyme activities were observed for all three1158 Br J Clin Pharmacol (2016) 81 1153–1164
Scaling factors for renal drug and xenobiotic glucuronidation clearancesubstrates when using either a pool of KCM or a pool of KMM.
The C : M ratios of enzyme activities for the pools of KCM and
KMM were 0.9, 0.9 and 1.4 for UGT 1A6, 1A9 and 2B7, respec-
tively (Table 2).
UGT content of human kidney microsomes and
UGT 1A9 and UGT2B7 supersomes
In this study the limit of detection for all UGT proteins inves-
tigated, except UGT1A8, was <1.0 pmol mg1 protein [20].
UGT 1A6, 1A9 and 2B7 were expressed in all MKM, KCM
and KMM samples analyzed (Figure 1). For MKM, the rank
order of mean UGT protein content was UGT1A9
(61.3 ± 20.1 pmol mg1) > UGT2B7 (37.6 ± 17.4 pmol mg1)
> > UGT1A6 (4.7 ± 1.4 pmol mg1) (Table 1). The content of
UGT 1A6, 1A9 and 2B7 protein was greater in KCM, with
C : M ratios of 2.7, 6.2 and 7.2, respectively (Table 2). In
KCM, the content of UGT1A6 varied approximately 5-fold
(range 1.2–6.1 pmol mg1), 4-fold for UGT1A9 (range 12.8–
56.2 pmol mg1) and 6-fold for UGT2B7 (range 7.4–
43.5 pmol mg1). An approximate 3-fold variation was
observed in KMM for UGT1A6 (range 0.8–2.6 pmol mg1),
UGT1A9 (range 3.9–9.9 pmol mg1) and UGT2B7 (2.5–
7.2 pmol mg1). By contrast, UGT 1A1, 1A3, 1A4, 1A5,
1A7, 1A8, 1A10, 2B4, 2B15 and UGT2B17 were not
expressed in MKM, KCM or KMM. UGT2B10 was absent in
all MKM samples (K12-K16) and in KCM and KMM for K2,
K10 and K11. The UGT1A9 (batch 2 228 592) and UGT2B7
(batch 38 943) contents of Supersomes were 553 pmol mg1
and 1593 pmol mg1, respectively.
Correlations between glucuronidation activities
and UGT protein contents
Rates of glucuronidation of DEF, PRO and AZT by MKM, KCM
and KMM were highly correlated with the content of UGT1A6
(rs = 0.87, P < 0.0001), UGT1A9 (rs = 0.85, P < 0.0001) andTable 3
Derived kinetic constants for morphine (MOR) and propofol (PRO) glucuron
sue, and predicted in vivo glucuronidation clearances (CLUGT) for kidney and
somes (MKM), pooled human liver microsomes (HLM), and recombinant h
Vmax*
(pmol min1 mg1 protein)
CLint,u
(μl min
Substrate/Enzyme Km* (μM)
PRO/MKM 17 ± 0.7 3070 ± 44 181
PRO/HLM 9.6 ± 0.5 880 ± 12.9 91.7
PRO/UGT1 A9 9.1 ± 0.03 997 ± 2.1 110
MOR(3-G)/MKM 492 ± 2.1 1756 ± 3.4 3.6
MOR(6-G)/MKM 455 ± 10 300 ± 2.0 0.66
MOR(3-G)/HLM 577 ± 10 2544 ± 16 4.4
MOR(6-G)/HLM 533 ± 22 570 ± 9.1 1.1
MOR(3-G)/UGT2B7 602 ± 0.4 835 ± 0.23 1.39
MOR(6-G)/UGT2B7 574 ± 5.8 183 ± 0.7 0.32
*Parameter ± standard error of parameter fit. †Unbound intrinsic clearance cal
6-glucuronidation.UGT2B7 (rs 0.94, P < 0.0001), (Figure 2), respectively. Analyses
between the contents of UGT enzymes identified significant cor-
relations between the pairs UGT1A6/UGT1A9 (rs = 0.71,
P < 0.0001), UGT1A6/UGT2B7 (rs = 0.76, P < 0.0001) and
UGT1A9/UGT2B7 (rs = 0.89, P < 0.0001). For individual data
refer to Supporting Information Table S2.
PRO and MOR glucuronidation kinetics
Kinetic parameters for PRO glucuronidation by MKM, HLM
and UGT1A9 determined in the presence of 2% BSA are
shown in Table 3. PRO glucuronidation by all enzyme sources
was well described by the Michaelis–Menten equation. Mean
Km values were 17, 9.6 and 9.1 μM for MKM, HLM and
UGT1A9, respectively. However, the mean Vmax value for
PRO glucuronidation by MKM was 3.5-fold higher than that
for HLM. Hyperbolic kinetics were similarly observed for
MOR 3- and 6-glucuronidation by MKM, HLM and recombi-
nant UGT2B7 supplemented with BSA. The mean Km values
for MOR 3- and 6-glucuronidation by the three enzyme
sources (+ BSA) ranged from 455 to 602 μM, consistent with
previous reports from this laboratory [37, 38]. In contrast to
PRO, Vmax values determined for MOR glucuronidation using
HLM were higher than those measured with MKM.
Predicted PRO and MOR CLUGT by kidney and
liver
MKM to HLM CLint,u,UGT (μl mg
1 min1) ratios were 2.0 for
PRO, and 0.8 and 0.6 for MOR(3-G) and MOR(6-G), respec-
tively (Table 3). Predicted PRO glucuronidation CLUGT by kid-
ney (0.11 ml min1 kg1) represented 12% of that in liver
while scaled total renal MOR glucuronidation CLUGT was 5%
of that in liver (Table 3). Extrapolated renal/hepatic PRO
CLUGT based on quantification of recombinant UGT1A9 pro-
tein was 7% and 6% of the values obtained with MKM and
HLM, respectively. Similarly for recombinant UGT2B7 scaledidation in the presence of 2% (w/v) BSA, scaled CLint,u,UGT g
–1 of tis-
liver. The protein sources were pooled mixed human kidney micro-
uman UGT1A9 and UGT2B7
,UGT†1 mg1 protein)
CLint,u,UGT
(ml min1 g1 tissue)
Predicted CLUGT
(ml min1 kg1)
Kidney Liver Kidney Liver
1.68 – 0.11 –
– 2.93 – 0.9
0.114 0.15 0.008 0.05
0.03 – 0.1 –
0.006 – 0.02 –
– 0.14 – 1.9
– 0.04 – 0.48
0.0003 0.002 0.0009 0.03
0.00007 0.0005 0.0002 0.007
culated as Vmax/Km.3-G =morphine 3-glucuronidation.6-G =morphine
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1.6% of CLUGT obtained with MKM and HLM, respectively.Discussion
The glucuronidation of numerous drugs and other xenobi-
otics by human kidney has been demonstrated in multiple
studies (see Introduction). However, estimates of renal drug
metabolic clearance have used either microsomal protein
per gram of liver (45 mg g1, [13]), the yield from rat kidney
(6 mg g1, [9, 41]) or a single report of 12.8 mg g1 [14]. The
latter study, which used 5 g of human kidney tissue (unspec-
ified region), reported a 3.8-fold variation in MPPGK (range
4.7–18.2 mg g1) and a 38% loss of microsomal protein dur-
ing preparation. Using approximately 1 g of mixed
cortical/medullary tissue from five subjects, we determined
ameanMPPGK of 9.3 mg g1 (range 6–12mg g1). Loss of mi-
crosomal protein during preparation was ~34%, comparable
with that of Al-Jahdari et al. [14], but less than the 47% re-
ported for human liver [29].
The MPPGK determined here is approximately 30% of the
value for human liver (32 mg g1) [16] and therefore estima-
tion of renal drug clearance using hepatic microsomal yield
data is clearly inappropriate. A lower microsome yield from
kidney in comparison with liver would be anticipated be-
cause of the diverse morphology of renal tubule cells that in-
cludes well-developed endoplasmic reticulum (ER) in the
cortical proximal tubule cells, but sparse ER in tubule cells
of the inner zone of the medulla [42]. Additionally, differ-
ences in the quantitative distribution of UGTs throughout
the human nephron mirror the cortical/medullary gradation
of ER [1, 43]. It is unknown if MPPGK changes with ageing,
but there were insufficient samples in this study to investi-
gate relationships between MPPGK and the age and gender
of the donors. (For individual data refer to Supporting Infor-
mation Table S2).
The mean rates of DEF, PRO and AZT glucuronidation
observed for MKM and paired KCM/KMM were reasonably
close in value, 18 999, 6309 and 1183 vs. 15 758, 5977
and 647 pmol-G min1 mg1. The difference in AZT
glucuronidation accords with the impact of alternative gene
splicing on the activity of UGT2B7 in kidney tissue [44]. Addi-
tionally, rates of DEF, PRO and AZT glucuronidation normal-
ized for UGT expression for pooled kidney microsomes are
comparable with the rates obtained with the individual kid-
ney microsomes comprising the pool, irrespective of whether
the enzyme source was KCM or KMM. Thus, the use of MKM
is an appropriate experimental tool for kidney-specific IV–
IVE models. Previous studies that have reported the use of
kidney microsomes for in vitro studies have not specified the
anatomic region and hence extrapolated kinetic data may
not reflect whole kidney metabolic clearance.
Consistent with other studies reporting lower UGT activ-
ity in the medulla than cortex, we found 1.4-, 5- and 11-fold
differences between cortex and medulla in the rates of
glucuronidation of DEF, PRO and AZT, respectively. The lower
activity in medulla equates with the approximate 3-, 6- and 7-
fold difference between KCM and KMM in the expression of
UGT 1A6, 1A9 and 2B7, respectively. As the region of kidney1160 Br J Clin Pharmacol (2016) 81 1153–1164used for preparation of microsomes impacts on
glucuronidation capacity [1], use of KCM will result in an
over-estimation and KMM in an under-estimation of CLint
via glucuronidation, potentially skewing the role of the kid-
ney in the glucuronidation clearance of drugs and xenobi-
otics. However, normalizing enzyme activity for UGT
expression negates the difference in glucuronidation capacity
between KCM and KMM. In addition to anatomic differences
in renal glucuronidation, cortical blood flow (4.7 ml g1
tissue min–1) exceeds that of the medulla (2.3 ml g1
tissue min–1) [45]. As noted previously, in the absence of
kidney-specific IV–IVE models use of perfusion-limited
kinetics and assumptions of the well-stirred model may bias
IV–IVE predictions [15].
This study is the first to quantify the UGT protein content
of MKM, KCM and KMM and confirms that UGT 1A6, 1A9
and 2B7 are the predominant forms expressed in human kid-
ney [19, 24]. With the exception of UGT 1A6 and 1A9, no
quantifiable protein was detected for any of the other UGT1A
enzymes investigated. These data support studies reporting
either UGT mRNA or UGT protein expression for UGT 1A6
and 1A9 in human kidney [17, 18, 46]. The 13-fold greater
abundance of UGT1A9 compared with UGT1A6 supports a
greater role for UGT1A9 in the renal metabolism of xeno-
and endo-biotics [8]. In contrast, UGT 1A1, 1A3, 1A8 and
1A10 were not detected, which accords with the lack of
mRNA expression in kidney [17, 46]. UGT 1A4, 1A5 and
1A7 mRNA expression has been reported [18, 46] but we
and Fallon et al. [19] found no evidence of the corresponding
UGT proteins. Absence of UGT 1A1 and 1A4 protein in renal
microsomes is supported by our observation of lack of β-E2
and TFP glucuronidation.
Similar to UGT 1A6 and 1A9, UGT2B7 protein was
detected in all MKM, KCM and KMM samples analyzed. On
average, UGT2B7 protein expression was approximately half
that of UGT1A9, consistent with the lesser contribution of
UGT2B7 to overall renal glucuronidation. Although mRNA
expression has been reported for UGT2B4 and UGT2B15/17
[46] the corresponding UGT proteins were not detected in
this and other studies [19, 24] highlighting the fact that
mRNA expression is not predictive at the protein level [47].
Additionally, we did not observe glucuronidation of the
UGT2B15/17 ‘probe’ substrate TST by kidney microsomes.
Significant correlations were observed here between UGT
1A6, 1A9 and 2B7 enzyme activity and UGT protein content
and between UGT1A6/UGT1A9, UGT1A6/UGT2B7 and
UGT1A9/UGT2B7 content. Previous studies have reported a
significant correlation between UGT1A6/UGT1A9 expression
using HLM [21, 48]. Correlations between UGT 1A6, 1A9 and
2B7 protein content may be explained by common regula-
tory factors including PXR, CAR, HNF-1α and HNF-4α [49–
51]. Additionally, UGT1A9 and UGT2B7 terminate the bio-
logical activity of arachidonic acid metabolites and hence
are integral to the regulation of renal haemodynamics [7, 8].
Based on experience with the IV–IVE of hepatic drug
glucuronidation clearance [30], the results presented here
provide an approach for the assessment of the relative contri-
bution of renal and hepatic drug and chemical clearance via
glucuronidation from in vitro data. As with the IV–IVE of
hepatically eliminated drugs the crucial first step is the accu-
rate prediction of in vitro CLint (Vmax/Km) with MKM as the
Scaling factors for renal drug and xenobiotic glucuronidation clearanceenzyme source (or maximal clearance where sigmoidal kinet-
ics are observed). Activation of MKMwith alamethicin is nec-
essary to remove the ‘latency’ associated with microsomal
UGTs [34] and, since the predominant UGT enzymes in
MKM are UGT 1A9 and 2B7, incubations were performed in
the presence of 2% (w/v) BSA to overcome the inhibition of
these enzymes by inhibitory long-chain unsaturated acids re-
leased from membranes during the course of an incubation
[15, 33, 52–54]. However, substrate binding to HLM and
BSA must be accounted for in the calculation of Km (and
hence CLint,u,UGT). The microsomal CLint,u,UGT may then be
scaled to the whole kidney CLint,u,UGT using the MPPGK
reported here (i.e. 9.3 mg g1), which in turn may be scaled
to renal glucuronidation clearance. Although the equation
for the well-stirred model was used here (and previously by
others [15]), its relevance to the prediction of renal drug
glucuronidation clearance in vivo is yet to be established,
especially considering blood flow in the cortex and medulla
differ [45].
Following this approach, the extrapolated renal
glucuronidation CLint,u,UGT of the UGT1A9 substrate PRO
and the UGT2B7 substrate MOR were determined here, along
with the predicted renal and hepatic glucuronidation
clearances for these drugs. The sum of the extrapolated
renal and hepatic PRO glucuronidation clearances was
1.01 ml min1 kg1 or 4.2 l h1 for a 70 kg person. PRO is
cleared in vivo by both UGT and cytochrome P450 mediated
oxidation, predominately UGT1A9 [33] and CYP2B6 [14]. As
indicated in Methods the estimated renal clearance via
glucuronidation in vivo is 57 l h1 [33]. Based on the com-
bined renal and hepatic in vitro kinetic data reported here
the predicted CLUGT compared with that observed in vivo is
substantially under-estimated. Of the total PRO
glucuronidation clearance predicted from the in vitro data, re-
nal glucuronidation accounted for 11% (i.e. 0.11 vs.
1.01 ml min1 kg1). A significant contribution of renal
glucuronidation to PRO elimination accords with the obser-
vation that extra-hepatic clearance may account for up to
27% of total clearance in patients undergoing liver transplan-
tation, although the separate renal metabolic clearances via
glucuronidation and oxidation were not determined [55].
Gill et al. [15] recently reported a comparison of the
glucuronidation of a number of compounds, including PRO,
by HLM and HKM. In contrast to our data (kidney : liver ratio
0.6), these authors noted a higher kidney : liver ratio (1.63)
for extrapolated PRO CLint,u,UGT. However, as noted by Gill
et al. [15], the effect of BSA on in vitro CLint,u,UGT with HLM
as the enzyme source was considerably lower than the ap-
proximate 10-fold increase expected for UGT1A9 substrates
and lower than the 11.2-fold increased they observed for
HKM. Had the BSA effect been similar to previous reports,
recalculating the data reported by Gill et al. [15] for the contri-
bution of the kidney to PRO glucuronidation clearance pro-
vides a value of 11%, identical to this study. Predicted CLUGT
observed here under-estimated the known clearance of PRO
by glucuronidation (viz. 57 l h1) by 93%. Similarly the in vitro
glucuronidation data generated by Gill et al. [15] under-
estimated known PRO CLUGT by approximately 75%. A num-
ber of factors may have contributed to the differences in pre-
dicted CLUGT between the two studies. In the study of Gill
et al. [15] in vitro CLint,u,UGT was estimated using the substratedepletion approach compared with the measurement of glu-
curonide formation here, the anatomical region used for
preparation of kidney microsomes was not specified and a
value for MPPGK of 12.8 mg g1 was employed. Nevertheless,
it is apparent that, despite the determination of MPPGK and
knowledge of renal UGT abundance, current IV–IVE ap-
proaches under-predict PRO glucuronidation clearance
in vivo.
Similar to PRO, the predicted renal glucuronidation clear-
ance of the UGT2B7 substrate MOR was also low (5%) com-
pared with the predicted hepatic clearance (0.12 vs.
2.38 ml min1 kg1), which is consistent with the lower ex-
pression of UGT2B7 in kidney observed here and by
Margaillan et al. [24]. The ratio MOR (3-G) : MOR (6-G) was
5 : 1 and 4 : 1 for MKM and HLM, respectively. Similar to
PRO, extrapolation of the combined hepatic and renal CLUGT
values for MOR 3- and 6-glucuronidation (10.1 l h1) under-
predicted the observed mean in vivo glucuronidation clear-
ance (approximately 56.2 l h1 [40]) by 82%. We have ob-
served previously that IV–IVE approaches similarly under-
predict the known in vivo glucuronidation clearance of the
UGT2B7 substrate AZT [34, 54, 56].
The contents of UGT 1A6, 1A9 and 2B7 reported here also
potentially allow the prediction of renal/hepatic drug
glucuronidation clearance in vivo from kinetic data generated
using recombinant human UGTs as the enzyme source. We
determined in vitro CLint,u,UGT values for PRO and MOR
glucuronidation by batches of Supersomes expressing
UGT1 A9 and UGT2B7, respectively. The specific contents of
these UGTs were determined (see Results) and, as anticipated
with over-expression, the UGT 1A9 and 2B7 contents of
Supersomes (pmol-UGT mg1) were 10-fold and 43-fold
greater than the respective pmol-UGT mg1 of MKM. How-
ever, this was not reflected in proportional increases in
glucuronidation activities. Compared with the observed total
PRO glucuronidation clearance of 57 l h1 the use of recombi-
nant UGT1A9 resulted in a substantial under prediction
(0.24 l h1) although the ratio of the predicted renal to he-
patic glucuronidation clearance by UGT1A9 (0.16) was simi-
lar to MKM : HLM (0.12). Total MOR glucuronidation
clearance (0.17 l h1) using recombinant UGT2B7 was <1%
of the predicted in vivo clearance. However, the ratios of
MOR(3-G) to MOR(6-G) were similar for all protein sources
MKM 6 : 1; HLM 4 : 1 and UGT2B7 5 : 1 (c.f. 5.4 in vivo) The
poor prediction accuracy based on recombinant enzymes
may be accounted for by the high levels of inactive protein
when UGTs are expressed in insect cells [57].
In conclusion, the cortex has a 5-fold greater abundance
of total UGT proteins and hence will have a greater
glucuronidation capacity for UGT 1A6, 1A9 and 2B7 sub-
strates than the medulla. This is particularly relevant for
UGT1A9 substrates as it is 2.7-fold more abundant in human
kidney (61.3 pmol mg1 microsomal protein) than in human
liver (approximately 23 pmol mg1, [20, 48, 58]. Our data
support the observation that predicted renal glucuronidation
CLint,u,UGT is 2-fold higher in kidney than liver for UGT1A9
substrates [15] and hence CLint,u,UGT should be included in
IV–IVE approaches for substrates glucuronidated by UGT1A9.
The renal expression of UGT1A6 and UGT2B7 is approxi-
mately half that of liver (9.7 and 80.7 pmol mg1, respec-
tively [20, 58]). Using renal UGT expression data from thisBr J Clin Pharmacol (2016) 81 1153–1164 1161
K. M. Knights et al.study and liver expression data from Fallon et al., [20] the kid-
ney : liver UGT expression ratios for UGT1A6 and UGT2B7 are
0.48 and 0.46. The latter accords well with the kidney : liver
scaled CLint,u,UGT ratios of 0.15–0.33 for glucuronidated drugs
primarily cleared by UGT2B7 [15] and indicates a greater role
normally for UGT2B7 in the hepatic metabolism of xenobi-
otics. However, in situations impacting on hepatic metabo-
lism (e.g. drug–drug interactions, poor metabolizer
phenotype, hepatic transporter defects, hepatic disease) or
in the determination of renal metabolite formation or toxic-
ity evaluations, renal glucuronidation by UGT2B7 and in-
deed UGT1A6 may be an important consideration. Further,
we show that the use of recombinant UGT 1A9 and 2B7 pro-
teins is appropriate for determining the contribution and
fractional metabolism of substrates but recombinant UGT
1A9 and 2B7 substantially under-predict CLUGT. Clearly fur-
ther work is still required on the development of relative ac-
tivity factors, intersystem extrapolation factors and kidney
specific IV–IVE models applicable for predicting renal meta-
bolic clearance in vivo.Competing Interests
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